TherapeuticsMD Inc. (NASDAQ: TXMD) was one of the biggest movers in the recent trading session, with the company’s stock currently changing hands at 0.1 points up or 4.08% higher on the previous close. So what do we make of this stock that is clearly one of the hottest on the market now? The TXMD stock is trading at $2.55 from a close of $2.45 on 01/15/20. The day’s price range saw the stock hit a low of $2.44, while the highest price level was $2.69 during the intraday trading.
Is the TXMD stock going to continue the plunge or will it steady in coming sessions to climb above its 5-day high price of $2.69. TherapeuticsMD Inc. (NASDAQ: TXMD) has a 52-week price range of between $1.82 and $6.09. Notably, the reduced performance in the current session comes on the back of condensed market activity for the stock, as its daily trading volume to 6027191, compared to its 3-months daily average volume of 3.76 million. In comparison, the average volume for the last 50 days stands at 3,490,320.
What about the stock’s price forecasts? TXMD had 8 analysts who offered their 12-month price predictions for the TherapeuticsMD Inc. shares. The group has given the stock a consensus price target of $8.36, with the lowest forecast being put at $2.50. The highest estimate by the 8 analysts is $16.00. The median price target estimate of $7.00 for the stock represents a 63.57% jump in value from the previous price of $2.55. Looking at the 52-week price ranges, the stock’s current price level is 40.11% from its 52-week high price and -58.13% down from its 52-week low in the same period.
TherapeuticsMD Inc. shares have surged 10.39% over the past week, but its 1-month performance is in the green at 10.87%. Its performance in the current quarter is down -34.87%, while that figure shoots to 8.51% over the past half-year period. Further, we see that the stock’s 12-month charts show that it has lost by -50.29%, with the year-to-date prices up by 5.37%.
The company has a market cap of 679.68 million and a return on assets (ROA) of -74.60%. In gauging how profitable company analysts and investors look at the respective company’s ROA, with returns above 5% generally regarded as good. Also important is the company’s return on equity (ROE), with TXMD’s at -457.90% indicating that the management is able to generate impressive income with whatever equity at their disposal. If you put your money on this stock, then a forecast ROI is at -76.20%.
But what do Wall Street analysts tracking this stock recommend, given that it has 266.54 million shares outstanding? 8 analysts polled have a consensus recommendation rating of 4.75, indicating that TXMD is a Buy stock at the moment. This mean rating was at 4.75 a month ago. Guggenheim called it a Buy stock on December 02, 2019, while H.C. Wainwright rated it a Buy in its note released on October 17, 2019. Of the 8 analysts, 0 analysts rate the TXMD stock as Overweight, while 1 of them rated it as a Hold. 7 analysts rate TherapeuticsMD Inc. as a Buy, while 0 suggested its Underweight. Only 0 analyst advised investors to sell.
Let’s glean at the company’s earnings forecasts for the current quarter and annual growth estimate for the next 5-year period. The analyst forecasts for this stock’s earnings per share (EPS) for the current quarter (Dec 2019) ranged from a low of -$0.24 per share to -$0.17 per share. The average estimate by the 8 analysts for the TXMD shares was -$0.19 a share, while the company’s last-quarter results returned an EPS of -$0.17. Looking at the current EPS trends, seven days ago, TXMD had its Dec 2019 estimates at -$0.19 per share while the stock’s EPS was forecasted at the -$0.19, a month ago.
Let’s briefly check out revenue growth estimates for the company, which is put at 152.30% in the current quarter. However, the next quarter should see net revenue growth of over 338.30%, with analysts forecasting the company’s 12-month growth estimates at 128.70%. 9 analysts have forecast that TherapeuticsMD Inc. will see its revenue growth net between $10.7 million and $13.8 million for the current quarter. The next quarter should see revenue returns of between $14.7 million and $20.5 million.The average revenue for the quarter is expected at $12.84 million, while for the next quarter, it jumps to $17.3 million. Sales growth for the year are estimated at 128.70%.